现实世界二线治疗模式的不可切除或晚期肝癌在中国:一个追溯的数据库研究研究
Jiahua Leng1,2, Jing Wu3, Rong Han4
1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Gastrointestinal Center, Unit III, Peking University Cancer Hospital and Institute, Beijing, China.
Journal of gastrointestinal oncology
|September 15, 2025
概括
向治疗,特别是雷戈拉费尼布,是中国最常见的晚期肝癌二线治疗方法. 现实数据显示,在国家药物补偿清单更新后,治疗模式发生了变化.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 现实世界的证据.
背景情况:
- 新兴药物为晚期肝癌 (HC) 提供了多样化的全身治疗选择.
- 将其列入国家补偿药物清单 (NRDL) 显著影响了二线 (2L) 治疗的临床实践.
- 了解中国的现实2L治疗模式至关重要.
研究的目的:
- 描述中国不可切除或晚期HC患者的现实世界2L治疗模式.
- 分析NRDL 2020版本实施前后的治疗趋势.
主要方法:
- 对接受2L治疗的成人不可切除或高级HC患者的回顾性分析.
- 数据来源于天津医疗保健和医疗大数据平台 (2018-2021年).
- 对治疗模式和结果的描述性分析,包括基于NRDL实施的子组分析.
主要成果:
- 向治疗是最常见的2L治疗 (75.6%),其中雷戈拉费尼布单一治疗是最常见的类型 (57.7%).
- 在NRDL实施后,观察到2020年CSCO指南推的2L治疗的使用率下降 (87.2%至59.2%).
- 在NRDL 2020实施后,趋势表明治疗持续时间增加和直接医疗成本降低.
结论:
- 向治疗,特别是雷戈拉菲尼布,主导着中国晚期HC的2L治疗.
- 需要进一步的研究来评估这些治疗在中国人口中的有效性和安全性.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


